解析表皮生长因子受体（ErbB）信号网络

Untangling the ErbB signalling network.

作者信息

Yarden Y, Sliwkowski M X

机构信息

Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel.

出版信息

Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37. doi: 10.1038/35052073.

DOI:10.1038/35052073

PMID:11252954

Abstract

When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signalling pathways, culminating in responses ranging from cell division to death, motility to adhesion. The network is often dysregulated in cancer and lends credence to the mantra that molecular understanding yields clinical benefit: over 25,000 women with breast cancer have now been treated with trastuzumab (Herceptin), a recombinant antibody designed to block the receptor ErbB2. Likewise, small-molecule enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clinical testing. What can this pathway teach us about translating basic science into clinical use?

摘要

当表皮生长因子及其相关分子与ErbB受体家族结合时，它们会触发一个丰富的信号通路网络，最终引发从细胞分裂到死亡、从运动到黏附等一系列反应。该网络在癌症中常常失调，这也印证了“分子层面的理解能带来临床益处”这一理念：目前已有超过25000名乳腺癌女性患者接受了曲妥珠单抗（赫赛汀）治疗，这是一种旨在阻断受体ErbB2的重组抗体。同样，针对ErbB1的小分子酶抑制剂和单克隆抗体也正处于临床试验的后期阶段。这条信号通路能在将基础科学转化为临床应用方面给我们带来哪些启示呢？